Brilinta Tablets and Neoral

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using cycloSPORINE and ticagrelor together may increase the blood levels and effects of both. You may need a dose adjustment or more frequent monitoring by your doctor to safely use these medications together. Contact your doctor if you have bleeding complications or you experience potential signs and symptoms of excessive cycloSPORINE blood levels such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration of cyclosporine and ticagrelor may increase the plasma concentrations of both drugs. Although the interaction has not been studied, competitive or noncompetitive inhibition of P-glycoprotein and CYP450 3A4 is possible, since these drugs are substrates as well as inhibitors of both the drug efflux transporter and isoenzyme. A case report of a 49-year-old man with a stable renal graft managed with cyclosporine (75 mg twice a day) who was initiated on ticagrelor for treatment of unstable angina pectoris showed an increase in previously stable cyclosporine trough concentrations and minor bleeding events 7 days after ticagrelor was started. Systemic cyclosporine exposure (AUC) was estimated to have increased from 1980 mcg*h/L up to 4740 mcg*h/L. Ticagrelor was discontinued and replaced by clopidogrel, and the daily dose of cyclosporine was reduced by 25 mg. Cyclosporine trough concentrations decreased within 13 days after ticagrelor therapy was stopped and the patient subsequently returned to stable cyclosporine trough levels and the original cyclosporine dose of 75 mg twice a day. There were no further reports of bleeding events.

MANAGEMENT: Caution is advised if cyclosporine and ticagrelor are used in combination. Cyclosporine blood levels and renal function should be monitored more closely whenever ticagrelor is added to or withdrawn from therapy, and the cyclosporine dosage adjusted as necessary. Patients should be advised to notify their physician if they experience bleeding complications or signs and symptoms of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions.

Brilinta Tablets

Generic Name: ticagrelor

Brand name: Brilinta

Synonyms: Brilinta

What is Brilinta Tablets?

Neoral

Generic Name: cyclosporine

Brand name: Gengraf, Neoral, Sandimmune, Sandimmune

Synonyms: Neoral (Capsules, Modified)

What is Neoral?